Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yemi Oluboyede

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Journal of Patient-Reported Outcomes|September 26, 2024
Economic burden and quality of life of caregivers of patients with sickle cell disease in the United Kingdom and France: a cross-sectional studyMartin Besser, Sian Bissell O'Sullivan, Siobhan Bourke, et al.
Pharmacoeconomics|April 21, 2011
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrencePeter S Hall, Claire Hulme, Christopher McCabe, et al.
BMJ Open|August 21, 2019
Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studiesElena Olariu, Marian Sorin Paveliu, Eugen Baican, et al.
Dermatology and Therapy|April 22, 2025
Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia AreataArash Mostaghimi, Adam Gibson, Georges Dwyer, et al.
Health and Quality of Life Outcomes|March 6, 2024
A time trade-off study to determine health-state utilities of transplant recipients with refractory cytomegalovirus infection with or without resistanceWaqas Ahmed, Louise Longworth, Yemi Oluboyede, et al.
Health and Quality of Life Outcomes|July 28, 2023
Population norms for the EQ-5D-3L and EQ-5D-5L in RomaniaElena Olariu, Raluca Caplescu, Luke Vale, et al.
Plos One|October 21, 2024
Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2Anish Patel, Walter Toro, Siobhan Bourke, et al.
International Journal of Environmental Research and Public Health|July 24, 2021
Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-OffMarian Sorin Paveliu, Elena Olariu, Raluca Caplescu, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 10, 2022
EQ-5D-5L: a value set for RomaniaElena Olariu, Wael Mohammed, Yemi Oluboyede, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2025
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trialNatalie Dennis, Kyle Dunton, Christopher Livings, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Journal of Patient-Reported Outcomes|September 26, 2024
Economic burden and quality of life of caregivers of patients with sickle cell disease in the United Kingdom and France: a cross-sectional studyMartin Besser, Sian Bissell O'Sullivan, Siobhan Bourke, et al.
Pharmacoeconomics|April 21, 2011
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrencePeter S Hall, Claire Hulme, Christopher McCabe, et al.
BMJ Open|August 21, 2019
Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studiesElena Olariu, Marian Sorin Paveliu, Eugen Baican, et al.
Dermatology and Therapy|April 22, 2025
Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia AreataArash Mostaghimi, Adam Gibson, Georges Dwyer, et al.
Health and Quality of Life Outcomes|March 6, 2024
A time trade-off study to determine health-state utilities of transplant recipients with refractory cytomegalovirus infection with or without resistanceWaqas Ahmed, Louise Longworth, Yemi Oluboyede, et al.
Health and Quality of Life Outcomes|July 28, 2023
Population norms for the EQ-5D-3L and EQ-5D-5L in RomaniaElena Olariu, Raluca Caplescu, Luke Vale, et al.
Plos One|October 21, 2024
Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2Anish Patel, Walter Toro, Siobhan Bourke, et al.
International Journal of Environmental Research and Public Health|July 24, 2021
Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-OffMarian Sorin Paveliu, Elena Olariu, Raluca Caplescu, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 10, 2022
EQ-5D-5L: a value set for RomaniaElena Olariu, Wael Mohammed, Yemi Oluboyede, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2025
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trialNatalie Dennis, Kyle Dunton, Christopher Livings, et al.
Pageof 5